LPA and hyperlipoproteinemia: Although clinical data underline the importance of reducing Lp(a) in CV risk reduction, only recently have clinical trials designed “ad hoc” for Lp(a) started, therefore, the current gold standard for treatment of Lp(a) hyperlipoproteinemia is still lipoprotein apheresis.